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Abstract
Background: Current standard for most of the locally advanced rectal cancers is preoperative chemoradiotherapy,
and, variably per institution, postoperative adjuvant chemotherapy. Short-course preoperative radiation with
delayed surgery has been shown to induce tumour down-staging in both randomized and observational studies.
The concept of neo-adjuvant chemotherapy has been proven successful in gastric cancer, hepatic metastases from
colorectal cancer and is currently tested in primary colon cancer.
Methods and design: Patients with rectal cancer with high risk features for local or systemic failure on magnetic
resonance imaging are randomized to either a standard arm or an experimental arm. The standard arm consists of
chemoradiation (1.8 Gy x 25 or 2 Gy x 25 with capecitabine) preoperatively, followed by selective postoperative
adjuvant chemotherapy. Postoperative chemotherapy is optional and may be omitted by participating institutions.
The experimental arm includes short-course radiotherapy (5 Gy x 5) followed by full-dose chemotherapy
(capecitabine and oxaliplatin) in 6 cycles before surgery. In the experimental arm, no postoperative chemotherapy is
prescribed. Surgery is performed according to TME principles in both study arms. The hypothesis is that short-course
radiotherapy with neo-adjuvant chemotherapy increases disease-free and overall survival without compromising local
control. Primary end-point is disease-free survival at 3 years. Secondary endpoints include overall survival, local control,
toxicity profile, and treatment completion rate, rate of pathological complete response and microscopically radical
resection, and quality of life.
Discussion: Following the advances in rectal cancer management, increased focus on survival rather than only on
local control is now justified. In an experimental arm, short-course radiotherapy is combined with full-dose
chemotherapy preoperatively, an alternative that offers advantages compared to concomitant chemoradiotherapy with
or without postoperative chemotherapy. In a multi-centre setting this regimen is compared to current standard with
the aim of improving survival for patients with locally advanced rectal cancer.
Trial registration: ClinicalTrials.gov NCT01558921
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Background
Over the past decades, management of rectal cancer has
evolved immensely leading to improved patient out-
comes. Although increased awareness, introduction of
screening programmes [1] and enhanced perioperative
care [2] have played roles in reducing mortality and
morbidity rates, two distinct therapeutic developments
have been of key importance. Firstly, surgical techniques
have been refined [3,4] and disseminated to the colorec-
tal surgical community [5]. Randomized controlled stud-
ies to prove the effects of new surgical techniques are
difficult to design and run, but observational data clearly
indicate benefits [6-8]. Secondly, (neo)adjuvant therapies
including radiotherapy and chemotherapy have become
integrated parts of rectal cancer management.
The Uppsala trial on pre- or postoperative radiother-
apy for rectal cancer was the starting point for a line of
development towards full acceptance for preoperative
short-course radiotherapy [9]. The Stockholm I trial run
in parallel [10], and the subsequent Swedish Rectal Can-
cer Trial with randomization between surgery alone and
preoperative radiotherapy with 5 Gy x 5 in resectable
rectal cancer showed not only improved local control
but also a survival benefit [11]. Criticism against these
trials regarding the quality of surgery performed was
met in the Dutch TME trial where only surgeons trained
in total mesorectal excision (TME) were operating. This
study confirmed improved local control with the use of
preoperative short-course radiotherapy although no sig-
nificant effects on survival could be seen, apart from cer-
tain subgroups [12,13]. Randomized data indicating
decreased short-term toxicity and no differences in long-
term oncologic outcomes and late toxicity compared to
preoperative chemoradiation in resectable rectal cancer
suggest that short-course radiation should be preferred
in these patients [14].
There is an overwhelming body of evidence supporting
adjuvant chemotherapy in colon cancer with indisput-
able effects on survival [15]. However, in rectal cancer
the corresponding evidence is weaker although a recent
metaanalysis [16] showed favourable outcomes with the
use of fluoropyrimidine-based chemotherapy. Another
systematic overview questioned its use, particularly after
preoperative chemoradiotherapy [17]. The risk of develop-
ing metachronous metastases in intermediate and locally
advanced rectal cancer is 25–65% [18-20] and systemic
chemotherapy aim to treat occult or micrometastatic dis-
ease that may later appear as distant metastases. At least
two arguments against postoperative delivery of chemo-
therapy can be brought up. Firstly, rectal cancer surgery
is connected with a substantial risk of postoperative
complications that may lead to patient inability to toler-
ate postoperative chemotherapy [21,22]. Secondly, in an
early disease phase when microscopic dissemination is
limited the efficacy of systemic chemotherapy would
theoretically be expected to be the greatest. Surgery,
particularly if extensive, may also accelerate tumor
growth [23,24]. Neoadjuvant chemotherapy has been
proven favourable in the management of colorectal liver
metastases [25], in gastric cancer [26,27] and is currently
being studied in colon cancer in the ongoing FOxTROT
trial [28].
Magnetic resonance imaging (MRI) is currently the
most accepted modality for preoperative local staging of
rectal cancer. Following the MERCURY-trial and further
studies there are criteria, although not yet universally ac-
cepted or used, for identification of patients with a high
risk of local and/or systemic relapse [29]. For patients
with early, clearly resectable tumours (also designated
“good”) surgery alone may provide excellent results with
respect to both local control and survival. In slightly more
advanced tumours, or “intermediate” following the ter-
minology of the European Rectal Cancer Consensus
Conference (EURECA-CC2) [30] or the European Society
of Medical Oncology (ESMO) Consensus Guidelines [31],
the increased risk of local recurrence justifies preoperative
radiotherapy. Short-course radiotherapy with immediate
surgery is a valid option in this situation as it reduces
the risk of recurrence by 60-70% [32,33]. However, in
this “intermediate” group (also designated “bad”), fre-
quently termed “locally advanced”, chemoradiation is the
preferred option by many [22,30,34]. In patients showing
high-risk features on MRI, tumours best termed “locally ad-
vanced”, or “ugly”, there is a substantial risk of treatment
failure either locally or systemically and chemoradiation is
the reference regimen, since the addition of chemotherapy
to conventionally fractionated radiotherapy improves local
control and cancer-specific survival [35]. However, some
patients may be considered too frail for chemoradiation
and three recent reports have shown promising results with
a strategy of delivering 5 Gy x 5 with delayed surgery
[36-38]. These studies, although non-randomized, support
the notion that also short-course preoperative radiation
results in down-staging if surgery is postponed. In
addition, a Dutch phase II trial [39], in which patients
with resectable metastatic rectal cancer were given
short-course radiation followed by preoperative chemo-
therapy including bevacizumab reported high response
rates and radical (R0) resection was achieved in 80% of
the patients.
Following evidence of tumour down-staging or down-
sizing with short-course radiation and arguments for
neo-adjuvant rather than adjuvant chemotherapy there
is a rationale for applying this concept on patients with
rectal cancer at high risk of local or systemic failure. The
present RAPIDO (Radiotherapy And Preoperative Induc-
tion therapy followed by Dedicated Operation) trial has
been designed to assess whether short-course radiation
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followed by up-front chemotherapy before surgery im-
proves 3-year disease-free survival (DFS) in patients with
locally advanced rectal cancer compared to conventional
chemoradiation with optional (according to institution pol-
icy) postoperative adjuvant chemotherapy.
Methods/design
Study design
The study is a two-arm prospective randomized multicentre
trial. The treatment algorithm is presented in Figure 1.
Study objectives
The study compares two different preoperative regimens
for locally advanced rectal cancer. The primary outcome
measure is DFS after 3 years. Secondary objectives are
to describe the toxicity profile, the rate of completion of
preoperative treatment, the fraction of patients with a
radical resection (R0) and to determine the rate of
pathological complete response (pCR). Furthermore,
local recurrence rate after 3 years follow-up, quality of
life (QoL), functional outcome and overall survival (OS)
are secondary endpoints.
Trial organisation
The RAPIDO-trial has been jointly designed by Uppsala
Akademiska Hospital, Sweden, Leiden University Med-
ical Center, The Netherlands, University Medical Center
Groningen, The Netherlands and Karolinska University
Hospital, Stockholm, Sweden. The trial is investigator
initiated and sponsors are the Dutch Colorectal Cancer
Group (DCCG) and the Nordic Gastrointestinal Tumour
Adjuvant Therapy Group (NGTATG). The RAPIDO-trial
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advanced 
rectal cancer
Randomization
Obstruction:
Diverting stoma
Standard Arm A
Chemo -
radiotherapy
Week 1-6
Response 
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Figure 1 Treatment algorithm.
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data management is financed by the Dutch and Swedish
cancer societies.
Coordination and monitoring
The trial is coordinated by the datacenter at Leiden
University Medical Center, The Netherlands. The trial of-
fice is responsible for overall trial management, trial registra-
tion (ClinicalTrials.gov NCT01558921, EudraCT number
2010-023957-12, CKS number 2011–4997, NL36315.042.11,
NTR 3230), database management and quality assurance.
A monitoring committee appointed by the trial sponsors
performs on-site monitoring of recruited patients according
to the ICH Harmonized Tripartite Guideline for Good
Clinical Practice (GCP).
Ethics, informed consent and safety
The final protocol was first approved by the ethics com-
mittees of Uppsala University, Sweden and University
Medical Center Groningen, The Netherlands. As centres
have and will join this trial, appropriate approval from
respective local ethics committee is obtained. This study
is conducted in accordance with the most recent version
of the Declaration of Helsinki and with the laws and reg-
ulations of each participating country. The protocol has
been written, and the study will be conducted according
to GCP. Written informed consent, signed and person-
ally dated, is obtained from each patient before inclusion
in the trial. Information that participation is voluntary
and the nature, scope and possible consequences of the
trial are explained to all patients by a physician. Prior to
when valid consent has been obtained, the investigator
will not undertake any measures specifically required only
for the trial. Serious adverse events (SAE) or suspected
unexpected serious adverse reactions (SUSAR), as defined
by the protocol, will be reported to the datacenter at
Leiden University Medical Center, The Netherlands
and to the respective national trial coordinators who
will report to competent authorities and ethical com-
mittees according to regulations applicable in each par-
ticipating country.
Statistics
DFS at 3 years is the primary end-point but the immediate
anti-tumour secondary endpoints R0 and pCR rates are
also of relevance. All efficacy analyses will be on an
intention-to-treat basis. Per-protocol analyses will be
performed as secondary analyses. Survival curves for
DFS and OS will be plotted using the method of Kaplan
and Meier. Cumulative incidence of local recurrence
will be computed accounting for death as competing
risk. Differences in survival will be tested with the log-
rank test. Hazard ratios and 95% confidence intervals
(CI) will be computed using Cox regression. All tests
will be two-sided. A table will present the completion
rate of the neo-adjuvant treatment, pCR frequency and
percentages, fraction of patients with a R0 resection
with 90 and 95% CI. Safety analyses will be based on
treatment received and will include only eligible patients.
Frequency and percentages for toxicity will be presented
according to the Common Terminology Criteria for
Adverse Events (CTCAE) version 4. All proportions will
be presented with 95% CI. Fifty percent DFS is described
in several studies with locally advanced rectal cancer
patients [18-20,35]. The hypothesis is that the new treat-
ment (Arm B) increases DFS after 3 years of follow-up
from 50 to 60%. This difference corresponds to a hazard
ratio of 0.737. A two-sided log rank test with a total of
452 DFS events achieves 90% power at α= 0.05 signifi-
cance level to detect a hazard ratio of 0.737 when the
proportion surviving in the control group is 50%. Based
on four years of uniform accrual and two years of add-
itional follow-up after the last patient has been included
(six years total), a total of 842 evaluable patients will
be required. With a drop-out of 5% the total number
of patients to be included is 885. Interim analyses are
planned with 50% and 75% of the DFS information for
efficacy. Both interim analyses will be conducted by a
team external to the sponsor team and each analysis
will include the primary efficacy endpoint and key
safety parameters.
Randomization and stratification
Randomization is done centrally at the datacenter at
Leiden University Medical Center, The Netherlands.
Patients will be stratified according to institution, per-
formance score (0 or 1), clinical T-stage (cT3 or cT4) and
clinical node status (cN- or cN+).
Patient selection
Inclusion in the RAPIDO trial requires that certain
tumour and patient criteria are met. A staging MRI of
specified quality is mandatory [40]. The inclusion and
exclusion criteria are presented in Table 1. It is recognised
that all MRI criteria indicate that the risk of systemic
failure is high whereas all do not indicate an increased
risk of local failure [29,41].
Preoperative therapy
Patients are randomized to one of two arms of preopera-
tive treatments. Arm A is considered the standard arm
and Arm B the experimental arm. In both arms, radiother-
apy is delivered with CT-based 3D-conformal treatment
planning with a defined pelvic clinical target volume
(CTV). Arm A consists of chemoradiation with a dose
to the planning target volume (PTV) of 45 Gy with 1.8 Gy
in 25 fractions given 5 times a week. The dose to the boost
PTV, encompassing the primary tumour and pathological
lymph nodes is 5.4 Gy in 3 fractions leading to a total dose
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of 50.4 Gy. It is possible to deliver the treatment as 25
fractions of 2 Gy at centres who use this as their standard.
An extra boost is possible to deliver towards the primary
tumour area at risk of non-radical surgery [42] with 1.8 -
2 Gy x 2–4. The extra boost can be given intraoperatively
(IORT). The radiotherapy is given in combination with
capecitabin in a dose of 825 mg/m2 twice daily on all days
of radiotherapy, including weekends. In Arm B, patients
will receive a total dose of 25 Gy to the pelvic PTV deliv-
ered in fractions of 5 Gy during 5 days with a maximum
overall treatment time of 8 days. An extra boost of 2 Gy x
2–3 is possible to deliver. With an optimal starting time
at 11–18 days after the last day of radiotherapy, patients
will receive neo-adjuvant chemotherapy. However, if
radiation-related toxicity occurs, commencement of chemo-
therapy may be delayed up until 4 weeks after termination
of radiotherapy. Chemotherapy is given in 3 week cycles
and consists of capecitabine 1000 mg/m2 twice daily,
day 1–14 combined with oxaliplatin 130 mg/m2 once
every 3 weeks. In total, 6 cycles of chemotherapy are
prescribed preoperatively. Treatment-related toxicity is
monitored through the preoperative phase and dose
modification can be made according to specified proto-
col schedules.
Response and resectabilty evaluation
Patients randomized to Arm A will undergo response
evaluation with MRI of the pelvis and computerized
tomography (CT) of chest and abdomen after the full
course of chemoradiation prior to surgery. Patients in
Arm B who have received short-course radiotherapy and
neoadjuvant chemotherapy will have MRI and CT after
the last cycle of chemotherapy but prior to surgery. An
additional response evaluation with MRI and CT is possible
to perform after the third neo-adjuvant cycle. Response
evaluation will be at a multidisciplinary team conference
and patients with progressive or irresectable disease will
receive palliative treatment. Radiological assessment will
be according to the Response Evaluation Criteria in
Solid Tumours (RECIST 1.1) [43].
Surgery and histopathology
In Arm A surgery should be performed 6–8 weeks after
termination of chemoradiation. In Arm B patients should
undergo surgery 2–4 weeks after the last cycle of
neoadjuvant chemotherapy. Surgical treatment should
not differ between the two trial groups and can be done
open or laparoscopically. Surgery should be performed
according to the TME principles, however, in tumours
located in the proximal part of rectum partial mesorectal
excision (PME) is permitted provided that a 5 cm distal
margin in mesorectum can be safely obtained. Surgery
may include anterior resection, abdominoperineal resec-
tion or a low Hartmann’s procedure. Potentially invaded
Table 1 Inclusion and exclusion criteria
Inclusion criteria
General Age ≥ 18 years
ECOG performance score ≤ 1
Written informed consent
Staging done within 5 weeks prior to randomization
Adequate potential for follow-up
Mentally and physically fit for chemotherapy
Adequate blood counts:
White blood cell count ≥4.0 x 109/L
Platelet count ≥100 x 109/L
Clinically acceptable haemoglobin levels
Creatinine levels indicating renal clearance ≥ 50 ml/min
Bilirubin < 35 μmol/L
Primary tumour
characteristics
Biopsy proven rectal adenocarcinoma*
Locally advanced tumour fulfilling at least one of
the following criteria on pelvic MRI:
cT4a
cT4b
cN2
Extramural vascular invasion (EMVI+)
Involved mesorectal fascia (MRF+)
Metastatic lateral lymphnodes (LN+)
Exclusion criteria Extensive tumour growth into sacrum above S3
Tumour involving lumbosacral nerve roots
Distant metastasis (M1)
Recurrent rectal cancer
FAP or HNPCC
Active Crohn’s disease or ulcerative colitis
Concomitant malignancies (except basocellular
carcinoma or in-situ cervical carcinoma)
Known DPD deficiency
Contraindications to MRI (e.g. pacemaker)
Inability to give informed consent
Concurrent uncontrolled medical condition
Any investigational treatment for rectal cancer
within past month
Pregnancy or breast feeding
Known malabsorption syndromes or lack of physical
integrity of upper gastrointestinal tract
Myocardial infarction within past 12 months or
clinically significant cardiac disease
Symptoms or history of peripheral neuropathy
ECOG Eastern Cooperative Oncology Group, * lower border of tumour < 16 cm
with a rigid rectoscope, MRI Magnetic resonance imaging, cT4a, cT4b and cN2:
Clinical stage according to TNM version 5, S3: sacral vertebra 3, FAP Familial
adenomatous polyposis, HNPCC Hereditary non-polyposis colorectal cancer,
DPD Dihydropyrimidine dehydrogenase.
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structures are resected en bloc with rectum. Pathological
evaluation of resected specimens will be according to
guidelines included in the study protocol. The 5th edition
of TNM will be used. In addition, circumferential resec-
tion margin (CRM) will be assessed and a margin of 1
mm or less is considered positive. CRM will be measured
both for the primary tumour and for lymph nodes or
tumour deposits, when present. Tumour regression grade
(TRG) will be assessed according a three-tier grade (no
regression, regression, and complete regression). Also,
the quality of the resected specimen will be evaluated
with separate scoring for the mesorectum and the anal
canal. After inclusion of the last patient, a committee of
experienced rectal pathologists will be appointed for
central review of histopathology.
Adjuvant chemotherapy and follow-up
Patients who receive chemoradiotherapy in Arm A can
be treated with postoperative chemotherapy according
to the local protocol of each participating centre. If pa-
tients are eligible for postoperative chemotherapy this
should consist of 8 cycles of capecitabine 1000 mg/m2
twice daily, day 1–14 combined with oxaliplatin 130 mg/m2
once every 3 weeks. Patients treated in Arm B with short-
course radiotherapy and neoadjuvant chemotherapy do
not receive any postoperative chemotherapy. A minimum
standardized follow-up schedule for all included patients
is prescribed. This includes visits with history including
morbidity/toxicity assessment, physical examination and
measurement of carcinoembryonic antigen (CEA) at 6, 12,
36 and 60 months. Toxicity will be assessed and recorded
according to CTCAEv4.0. QoL assessment using EORTC
questionnaires QLQ-C30 and QLQ-CR29 will be performed
at 36 and 60 months. All patients will also have CT of
thorax and abdomen (or chest x-ray and liver ultrasonog-
raphy) at 12 and 36 months. All suspicious findings should
prompt further evaluation and examinations.
Translational research
It is highly desirable to attach translational research to
provide insights to prognosis and prediction of response
to radiation and chemotherapy to the RAPIDO-trial.
Analyses of both tumour tissue and serum/plasma with
tissue microarray, proteomics and genomics would all
generate increased knowledge. Hence, a schedule for col-
lection of serum/plasma and of fresh tissue for freezing, at
different stages of treatment in each arm, is defined in the
study protocol. Pending on local resources and regula-
tions, participation in the translational part of RAPIDO
is optional.
Discussion
Improved staging, introduction of multidisciplinary
decision-making, refined surgery and appropriate use of
preoperative radiotherapy, together with quality assess-
ment by pathology and registries have all contributed to
substantially lowering rates of local recurrence in rectal
cancer from historical figures of above 30% to below
10% in many cohorts. Although there are certain sub-
groups who still suffer a high risk of not having R0
surgery or a local failure, the problem of local control
can be seen as solved for a majority of rectal cancer
patients. However, the improvements regarding local con-
trol achieved over the past decades are not matched by
same-size improvements with respect to survival. Without
compromising local therapy, it may therefore be justified
to shift focus from local control to systemic control and
survival when designing trials aiming at further develop-
ment of rectal cancer treatment.
The primary aim of adjuvant systemic chemotherapy
is to treat occult disease dissemination that may later
occur as distant metastases. Current standard for locally
advanced rectal cancer includes preoperative chemo-
radiation but, because of the risk of toxicity, dosage of
chemotherapeutic agents must be reduced which may
negatively affect the systemic efficacy. In many centres
additional chemotherapy is administered postoperatively.
However, since rectal cancer surgery is afflicted with
high rates of postoperative complications, a substantial
number of eligible patients are not fit to receive chemo-
therapy postoperatively [21,22,44]. In addition, when
preoperative chemoradiation is administered (5 weeks)
followed by surgery after 6–8 weeks and patients having
to recover after surgery for 5–6 weeks, postoperative
chemotherapy for suspected occult metastases cannot be
delivered until after 4–5 months. On the other hand,
neo-adjuvant chemotherapy yields favourable outcomes
in oesophageal and gastric cancer [26,27], in colorectal
hepatic metastases [25] and is currently investigated in
primary colon cancer [28]. In contrast to these trials, in
which chemotherapy is delivered pre- and postopera-
tively, all chemotherapy is given preoperatively in the
experimental arm of the RAPIDO-trial. This was also
the regimen in the Dutch “M1”-trial [39]. In this trial
50 patients with metastatic rectal cancer received
short-course radiation followed by 6 cycles of full-dose
capecitabine/oxaliplatin and bevacizumab preoperatively.
The completion rate for all 6 cycles of chemotherapy was
85% and more than 90% received 4 cycles or more, and
toxicity reported was mostly mild. Thus, the assumption
that preoperatively administered chemotherapy is more
likely to be accepted in full-dose than concomitant or
postoperative appears to be valid.
Two randomized trials have compared short-course pre-
operative radiotherapy to preoperative chemoradiation in
patients with resectable rectal cancer [45,46]. No evidence
that chemoradiation was superior concerning local control
or survival was provided in these studies. Furthermore,
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there were no indications of differences in late toxicity
between the two regimens and short-course radiation
resulted in less acute toxicity [14]. In these studies, in
which patients underwent surgery the immediate week
following short-course radiotherapy down-staging occurred
to a much greater extent in patients who had received
chemoradiation with delayed surgery. However, in an
interim analysis of the on-going Stockholm III trial, also
in resectable (intermediate stage) rectal cancer, the rate
of pCR after short-course radiotherapy with delayed sur-
gery was 12.5% [47]. Additionally, there are also other ran-
domized data [39] and observational data [36-38] indicating
a down-staging effect of short-course radiotherapy, given
that surgery is after a delay. Among patients who under-
went resection of the primary tumour in the “M1”-trial
(approximately 75% with T3/T4N+ tumours), 91% had a
R0 resection and pCR was found in 27% [39]. None of the
included patients was considered inoperable because of
primary tumour progression and only one patient suffered
local symptoms which occurred due to massive tumour
response with tumour necrosis and an abscess. The obser-
vational data from Stockholm also indicate that the risk of
tumour progression during the “waiting time” is low even
if chemotherapy is not administered in this period [38,47].
With this background, a rationale to test short-course
radiation also for the locally advanced tumours appears
to exist.
The RAPIDO-trial is designed with the aim of improving
survival without compromising local control in patients
with locally advanced rectal cancer. The aforementioned
support in the literature for down-staging following short-
course radiation with delayed surgery and the rationale
for neo-adjuvant chemotherapy opens a window to test
the combination of these two concepts, and to compare
results with current standard being preoperative chemo-
radiotherapy with or without adjuvant chemotherapy.
Although it is reasonable to assume that neo-adjuvant
chemotherapy not only has systemic effects but also acts
on the primary tumour it would be difficult to gain ac-
ceptance for a trial in which surgery is postponed after a
prolonged chemotherapy period. Even if chemotherapy
with the addition of biologics has improved substan-
tially during the past decade [48], the medical therapy
has limited cell kill effect and is the weakest component
in the treatment armamentarium. The initial 5 Gy x 5
will prevent local progression during the prolonged
chemotherapy aimed at killing all potential subclincal
cancer cells, without postponing the start of the sys-
temic therapy more than marginally. Most adjuvant
schedules in colorectal cancer consist of 8 cycles (24
weeks) of chemotherapy but in the “M1”-trial only 6
cycles were given preoperatively [39], an approach that
reduces the “waiting time” between short-course radi-
ation and surgery. Bevacizumab was included in that
trial but there is no evidence supporting an effect of
either bevacizumab or cetuximab against sub-clinical
disease [49,50] which renders it superfluous in the
RAPIDO setting.
In the RAPIDO-trial, the logistically simple approach
with initial local therapy with short-course radiotherapy
followed by systemic adjuvant full-dose up-front chemo-
therapy in 6 cycles, before local treatment is finalized
with surgery according to TME-principles, is being
explored. If this concept in the RAPIDO trial yields
improved survival with maintained results regarding
local control, the established management of locally
advanced rectal cancer with preoperative chemoradiation
is challenged.
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